TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  The Motley Fool

Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday

The Motley Fool Logo The Motley Fool By Eric Volkman
Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday

Travere Therapeutics stock surged nearly 14% on Wednesday following bullish analyst notes. Jefferies analyst Maury Raycroft identified Travere as a potential takeover candidate and highlighted its drug Filspari as having blockbuster potential. Cantor Fitzgerald reported that the FDA appears flexible on approving Filspari for treating focal segmental glomerulosclerosis (FSGS), with an FDA decision expected by January 13, 2026.

Insights
TVTX   positive

Stock gained 13.91% on positive analyst coverage highlighting blockbuster drug potential and takeover candidacy. FDA approval signals for Filspari in a new indication (FSGS) are encouraging, with decision expected January 13, 2026. The drug already has approval for treating IgAN since early 2024.